PHASQ — PhaseBio Pharmaceuticals Share Price
Last trade - 00:00- $0.00m
- -$3.73m
- $10.83m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -12738.63% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.67 | 2.36 | 0.32 | 10.83 | 9.32 | 9.22 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapies for cardiovascular diseases. Its lead product candidate, bentracimab (also known as PB2452), is a novel reversal agent for the antiplatelet drug ticagrelor. Ticagrelor is an antiplatelet therapy widely prescribed to reduce the rates of death, heart attack and stroke in patients with acute coronary syndrome (ACS), or who have previously experienced a heart attack. Ticagrelor binds to platelets to prevent them from forming blood clots that could restrict blood flow. The Company is also developing its preclinical product candidate, PB6440, an oral selective aldosterone synthase inhibitor for treatment-resistant hypertension. The Company is leveraging ELP biopolymer technology to evaluate additional preclinical and discovery-stage candidates. Its focus is on proteins and peptides that are scientifically or clinically validated.
Directors
- Clay Thorp NEC
- Jonathan Mow CEO (56)
- John Sharp CFO (56)
- Glen Burkhardt VPR (62)
- Kristophe Hanson VPR (49)
- Susan Arnold VPR (46)
- Michael York VPR (56)
- Jonathan Birchall OTH
- John Lee OTH (53)
- William Humphries DRC (55)
- Edmund Harrigan IND (68)
- Nancy Hutson IND (71)
- Caroline Loewy IND (54)
- Alex Sapir IND (54)
- Richard van den Broek IND (55)
- Last Annual
- December 31st, 2021
- Last Interim
- June 30th, 2022
- Incorporated
- January 10th, 2002
- Public Since
- October 18th, 2018
- No. of Shareholders
- 50
- No. of Employees
- 60
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 49,858,116
- Address
- 1 Great Valley Pkwy Ste 30, MALVERN, 19355-1423
- Web
- https://phasebio.com/
- Phone
- +1 6109816500
- Auditors
- KPMG LLP
Upcoming Events for PHASQ
Similar to PHASQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 22:39 UTC, shares in PhaseBio Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in PhaseBio Pharmaceuticals last closed at $0.00 and the price had moved by -99.83% over the past 365 days. In terms of relative price strength the PhaseBio Pharmaceuticals share price has underperformed the S&P500 Index by -99.86% over the past year.
The overall consensus recommendation for PhaseBio Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
PhaseBio Pharmaceuticals does not currently pay a dividend.
PhaseBio Pharmaceuticals does not currently pay a dividend.
PhaseBio Pharmaceuticals does not currently pay a dividend.
To buy shares in PhaseBio Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in PhaseBio Pharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for PhaseBio Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PHASQ
Based on an overall assessment of its quality, value and momentum PhaseBio Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PhaseBio Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $0.00, shares in PhaseBio Pharmaceuticals were trading -99.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The PhaseBio Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
PhaseBio Pharmaceuticals' management team is headed by:
- Clay Thorp - NEC
- Jonathan Mow - CEO
- John Sharp - CFO
- Glen Burkhardt - VPR
- Kristophe Hanson - VPR
- Susan Arnold - VPR
- Michael York - VPR
- Jonathan Birchall - OTH
- John Lee - OTH
- William Humphries - DRC
- Edmund Harrigan - IND
- Nancy Hutson - IND
- Caroline Loewy - IND
- Alex Sapir - IND
- Richard van den Broek - IND